This 2015 study published in Cancer Research investigates the impact of rapamycin on antitumor immunity, particularly focusing on CD8+ T-cell responses and the efficacy of therapeutic cancer vaccines. The researchers found that rapamycin treatment impaired the expansion and function of tumor-specific CD8+ T cells, leading to reduced cytotoxic activity against
